We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

119 hedge funds and large institutions have $546M invested in Theravance Biopharma in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 49 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

44% more call options, than puts

Call options by funds: $431K | Put options by funds: $299K

5% more funds holding

Funds holding: 113 → 119 (+6)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

4.37% less ownership

Funds ownership: 95.69% → 91.32% (-4.4%)

16% less capital invested

Capital invested by funds: $653M → $546M (-$106M)

41% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 49

Holders
119
Holders Change
+6
Holders Change %
+5.31%
% of All Funds
1.87%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
16
Increased
29
Reduced
49
Closed
10
Calls
$431K
Puts
$299K
Net Calls
+$132K
Net Calls Change
-$1.35M

Top Buyers

Rank Fund Capital Flow
1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$4.28M
2
Jane Street
Jane Street
New York
+$3.35M
3
HF
HRT Financial
New York
+$3.32M
4
JFG
Jefferies Financial Group
New York
+$3.31M
5
SG Americas Securities
SG Americas Securities
New York
+$1.34M

Top Sellers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
-$33.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$15.5M
3
Bank of America
Bank of America
North Carolina
-$14.3M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.28M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$4.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$2.31M -$1.43M -129,676 -37%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$2.24M +$67.8K +6,139 +3%
Macquarie Group
28
Macquarie Group
Australia
$2.16M – – –
Wellington Management Group
29
Wellington Management Group
Massachusetts
$1.89M +$464K +41,999 +30%
N
30
Nuveen
North Carolina
$1.63M +$31.1K +2,819 +2%
SG Americas Securities
31
SG Americas Securities
New York
$1.56M +$1.34M +121,126 +404%
Tudor Investment Corp
32
Tudor Investment Corp
Connecticut
$1.26M +$144K +13,031 +12%
Swiss National Bank
33
Swiss National Bank
Switzerland
$1.13M – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$1.09M +$211K +19,136 +22%
ECM
35
ExodusPoint Capital Management
New York
$1.07M +$1.14M +103,681 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$976K -$4.3M -389,500 -81%
CS
37
Credit Suisse
Switzerland
$904K -$801K -72,555 -45%
PP
38
PDT Partners
New York
$850K -$2.24K -203 -0.2%
Citadel Advisors
39
Citadel Advisors
Florida
$839K +$171K +15,441 +24%
MAM
40
Martingale Asset Management
Massachusetts
$814K +$21K +1,901 +2%
AllianceBernstein
41
AllianceBernstein
Tennessee
$805K – – –
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$741K +$791K +71,604 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$673K -$40.3K -3,654 -5%
UBS AM
44
UBS AM
Illinois
$666K – – –
Marshall Wace
45
Marshall Wace
United Kingdom
$619K +$660K +59,812 New
RA
46
Royce & Associates
New York
$611K – – –
NSEDCP
47
NJ State Employees Deferred Compensation Plan
New Jersey
$602K – – –
Two Sigma Investments
48
Two Sigma Investments
New York
$601K -$3.3M -298,809 -84%
Legal & General Group
49
Legal & General Group
United Kingdom
$592K +$4.43K +401 +0.7%
Ensign Peak Advisors
50
Ensign Peak Advisors
Utah
$587K – – –
1
2
3 4 5

TBPH Hedge Fund Activity: Q2 2023 in Review

119 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2023, worth a combined $546M — down 16% from $653M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new TBPH positions and 10 closed out — a net gain of 6 holders — while 29 added to existing stakes and 49 trimmed.

The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $4.28M. The largest seller was Baupost Group, cutting an estimated $33.1M.

  • 119 institutional investors held Theravance Biopharma (TBPH) as of Q2 2023, up from 113 in Q1 2023.
  • Funds reported $546M of Theravance Biopharma stock for Q2 2023, down 16% quarter-over-quarter.
  • 16 funds opened new Theravance Biopharma positions in Q2 2023 and 10 closed out, a net change of +6 holders.
  • The largest Theravance Biopharma buyer in Q2 2023 was Pictet Asset Management (Switzerland), an estimated $4.28M added.
  • The largest Theravance Biopharma seller in Q2 2023 was Baupost Group, an estimated $33.1M sold.

Based on aggregated 13F filings for Q2 2023.